

U.S. Patent Appl. No. 10/728,947- Mockel *et al.*
Attorney Docket No.: 021123-0306724

II. AMENDMENT TO THE CLAIMS

1-23. (Canceled)

24. (Currently Amended) An isolated nucleic acid comprising a ~~nucleotide~~ polynucleotide sequence selected from the group consisting of:

(a) ~~a nucleotide~~ polynucleotide sequence ~~as set forth in~~ SEQ ID NO: 1;
and

(b) a polynucleotide sequence encoding a polypeptide sequence SEQ ID
NO: 2; and

~~(b)(c)~~ a nucleotide sequence complementary to (a) or (b).

25. (Previously Presented) An isolated nucleic acid according to claim 24, wherein one or more of the codons in said SEQ ID NO: 1 are replaced with a degenerate codon.

26. (Currently Amended) An isolated nucleic acid according to claim 24, wherein said nucleotide sequence comprises one or more functionally neutral sense mutations ~~that do not alter the enolase polypeptide activity~~ wherein the changes in the polynucleotide sequence do not alter the encoded enolase polypeptide or its activity.

27. (Canceled)

28. (Previously Presented) An isolated nucleic acid comprising nucleotides encoding a protein with the amino acid sequence of SEQ ID NO: 2.

29. (Canceled)

30. (Canceled)

31. (Currently Amended) An isolated nucleic acid comprising a nucleotide sequence selected from the group consisting of:

(a) ~~the nucleotide~~ a polynucleotide sequence ~~as set forth in~~ SEQ ID NO: 3;

U.S. Patent Appl. No. 10/728,947- Mockel *et al.*
Attorney Docket No.: 021123-0306724

- (b) a ~~nucleotide~~ polynucleotide sequence encoding ~~the~~ a polypeptide ~~sequence as set forth in~~ SEQ ID NO: 4; and
- (c) a ~~nucleotide~~ polynucleotide sequence complementary to (a) or (b).

32. (Currently Amended) A vector comprising the isolated nucleic acid ~~of any one of claims 24-31~~ of any one of claims 24-26, 28 or 31.

33. (Currently Amended) The vector of ~~claim 35~~ claim 32, wherein said vector is an expression vector.

34. (Currently Amended) ~~[[A]]~~ An isolated host cell comprising the vector of claim 32.